| Date | Title | Description |
| 30.06.2025 | “Stop censoring our bodies”: 190+ women's healthtech leaders demand action from big tech | More than 190 organisations, founders, health professionals and campaigners have co-signed an open letter calling on social media platforms to end the routine censorship of women’s health content online.
Published by CensHERship and The Cas... |
| 06.09.2022 | She's A CEO, Not A Female CEO | Saundra Pelletier, Chief Executive Officer, President, and Executive Director of Evofem Biosciences (NASDAQ: EVFM) |
| 11.07.2022 | Evofem’s Wild Ride | Evofem's Phexxi is a hormone-free contraceptive for women. Image courtesy of Evofem Biosciences
The Supreme Court ruling to end federal abortion protections in the U.S. has sent San Diego-based Evofem Biosciences' stock on a rocket ride in ... |
| 28.06.2022 | Birth-control drugmaker Evofem Biosciences has spiked 240% since the Supreme Court's decision to overturn Roe vs. Wade | Evofem Biosciences shares spiked 240% in the past two days following the overturning of Roe vs. Wade.
The drugmaker owns Phexxi, one of the few non-hormonal birth control options available.
Advertisement
Evofem Biosciences shares extended t... |
| 20.04.2022 | Women Raising Capital: How I Worked Around Obstacles And Raised More Than $500 Million | Saundra Pelletier, Chief Executive Officer, President, and Executive Director of Evofem Biosciences (NASDAQ: EVFM) |
| 09.02.2022 | FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences | SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the... |
| 19.01.2022 | Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021 | SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contra... |
| 12.01.2022 | Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women | SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to... |
| 16.12.2021 | Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention | SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion'... |
| 09.12.2021 | Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021 | SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021.
Total monthly prescriptions (TRx) of Phexxi® (lactic... |
| 22.11.2021 | Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023 | SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its April 2020 Securities Purchase and Security Agreement to Jun... |
| 16.11.2021 | Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update | SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021.
"We are... |
| 10.11.2021 | Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive | SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS (Comisión Fede... |
| 20.10.2021 | Evofem Biosciences : "House Rules" Delivers Strong Initial Results and Drives Phexxi Growth | SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced significant initial results of "House Rules," its national direct-to-consumer (DTC) campaign with celebrity spokeswoman Annie Murphy... |
| 12.10.2021 | Evofem Biosciences : Announces $10 Million Registered Direct Offering of Series B Preferred Stock | SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sa... |
| 12.10.2021 | Evofem Biosciences : Announces $10 Million Registered Direct Offering of Series B Preferred Stock - Form 8-K | Evofem Biosciences Announces
$10 Million Registered Direct Offering of Series B Preferred Stock
-- Provides Runway into Q1 2022 --
SAN DIEGO, CA, October 12, 2021 - Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered... |
| 27.09.2021 | Evofem Biosciences : Announces Publication in Peer-Reviewed Journal Advances in Therapy | SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the pee... |
| 21.05.2021 | Evofem Biosciences Announces Closing of $50 Million Public Offering | |
| 21.05.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : Announces Closing of $50 Million Public Offering | SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants... |
| 18.05.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : Announces Pricing of $50 Million Public Offering | SAN DIEGO, May 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of its previously announced underwritten public offering of 50,000,000 shares of its common stock and accompanying short-term warran... |
| 17.05.2021 | Evofem Biosciences Announces Pricing of $50 Million Public Offering | |
| 17.05.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : Announces Proposed Public Offering | SAN DIEGO, May 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock (or pre... |
| 17.05.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021 | SAN DIEGO, May 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that new research on its investigational drug EVO100 for the prevention of chlamydia and gonorrhea in women will be highlighted in a poster pre... |
| 17.05.2021 | New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021 | |
| 12.05.2021 | Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women | |
| 28.04.2021 | Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting | |
| 21.04.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum | SAN DIEGO, April 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the company will deliver the keynote address and present two poster presentations on Phexxi® (lactic acid, citric acid, potassium bitartrate)... |
| 21.04.2021 | Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum | |
| 29.03.2021 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences : Announces Closing of Public Offering of Common Stock | SAN DIEGO, March 29, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share. Evofem's agg... |
| 29.03.2021 | Evofem Biosciences Announces Closing of Public Offering of Common Stock | |
| 24.03.2021 | Evofem Biosciences Announces Proposed Public Offering of Common Stock | |
| 24.03.2021 | Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock | |
| 17.03.2021 | Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact | |
| 16.03.2021 | Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention | |
| 16.03.2021 | Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention | SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecolog... |
| 18.02.2021 | New $300 Million Venture Fund Spotlights Role Of Women In Venture Capital And Public Health | A U.S.-based venture capital firm, Adjuvant Capital, has just announced a new $300 million fund, counting the Bill & Melinda Gates Foundation among its investors. The fund is focused on accelerating the development of medical innovation... |
| 16.02.2021 | Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for Women | |
| 04.02.2021 | Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer | |
| 11.12.2020 | Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi® | |
| 15.10.2020 |
Evofem Biosciences Scores $25M
| San Diego-based Evofem Biosciences, a biopharmaceuticals firm which is developing products to prevent urogenital chlamydia and gonorrhea in women, and which also markets a vaginal contraceptive gel, saysi t has raised $25M in a strategic in... |
| 15.10.2020 | Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital | |
| 03.08.2020 | EVOFEM BIOSCIENCES, INC.
Evofem Biosciences' : CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life Sciences | SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential a... |
| 03.06.2020 |
Evofem Looks To Raise $100M In Additional Public Offering
| San Diego-based Evofem Biosciences, a publicly held, biopharmaceuticals company which is developing products in the area of women's sexual and reproductive health, says it has priced approximately $100M in common stock to the public. The co... |
| 29.04.2020 | Evofem Biosciences has received $15M in a private securities purchase, and may receive up to $10M more if the company meets specific funding requirements defined in the agreement | - |
| 27.04.2020 |
Evofem Biosciences Gains $25M In Convertible Note
| San Diego-based biopharmaceuticals developer Evofem Biosciences, a publicly held developer of biopharmaceuticals aimed at contraception, says it has received $25M in a convertible note financing. The company says it has received $15M of tha... |
| 11.06.2019 |
Evofem Biosciences Raises $50M More
| San Diego-based Evofem Biosciences, a biopharmaceuticals firm developing women's sexual and reproductive health products, announced late Monday that it has received $50M more in funding, from PDL BioPharma. The funding is part of a larger, ... |
| 04.08.2016 |
Evofem Raises $25M
| San Diego-based EVOFEM, a biotechnology firm developing new contraceptives for the women's reproductive health market, announced this morning that it has raised $25M in a Series D funding round. The funding came from Woodford Investment Man... |
| 08.12.2009 | EVOFEM Receives $25M Private Equity Investment | EVOFEM, Inc., a La Jolla, San Diego, CA-based women’s healthcare company, has announced that it has recently received a $25m investment from an undisclosed private equity firm in Europe.
EVOFEM currently markets feminine hygiene products an... |
| - | Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact | SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birt... |
| - | Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update | SAN DIEGO, March 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2020.
"2020 was... |
